4883 Stock Overview
Engages in the research and development of therapeutics to treat patients with serious genetic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Modalis Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥100.00 |
| 52 Week High | JP¥203.00 |
| 52 Week Low | JP¥62.00 |
| Beta | 0.13 |
| 1 Month Change | -24.81% |
| 3 Month Change | -0.99% |
| 1 Year Change | -1.96% |
| 3 Year Change | -83.58% |
| 5 Year Change | n/a |
| Change since IPO | -95.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4883 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -9.9% | -1.7% | -1.5% |
| 1Y | -2.0% | 18.5% | 13.7% |
Return vs Industry: 4883 underperformed the JP Biotechs industry which returned 18.5% over the past year.
Return vs Market: 4883 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 4883 volatility | |
|---|---|
| 4883 Average Weekly Movement | 19.6% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4883's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4883's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Haruhiko Morita | modalistx.com |
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd.
Modalis Therapeutics Corporation Fundamentals Summary
| 4883 fundamental statistics | |
|---|---|
| Market cap | JP¥6.94b |
| Earnings (TTM) | -JP¥1.87b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs 4883 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4883 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.87b |
| Earnings | -JP¥1.87b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -26.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 8.4% |
How did 4883 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 13:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Modalis Therapeutics Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akinori Ueda | Goldman Sachs |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Tomohiro Tanaka | SMBC NIKKO |